ArticleBMC health services research2026
Costs related to atherosclerotic cardiovascular disease in Brazil: analysis from the perspective of the society.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerotic cardiovascular disease (ASCVD)-including ischemic heart disease (IHD), ischemic stroke (IS), and peripheral arterial disease (PAD)-is a leading cause of death and disability worldwide, creating a significant socioeconomic burden. In Brazil, ASCVD accounts for most cardiovascular-related hospitalizations and deaths; comprehensive national estimates of societal costs for IHD, IS, and PAD are still limited. This study aims to estimate the direct and indirect societal costs of IHD, IS, and PAD in Brazil from both public and private healthcare perspectives, and to project their economic burden for the 2025-2029 period.
methodsData were extracted from official national databases, including DATASUS (public sector), TISS (private sector), SIM (mortality), and InfoLogo (social security). Direct medical costs were derived from hospitalizations recorded between 2008 and 2023. Indirect costs included productivity losses due to absenteeism and premature mortality among individuals aged 14-64 years. Future costs were projected using the Exponential Smoothing with Error, Trend, and Seasonality (ETS) model.
resultsASCVD is projected to cause over 600,000 hospitalizations annually in Brazil, generating direct medical costs exceeding BRL 5.9 billion in 2029. Indirect costs related to premature mortality and absenteeism will reach approximately BRL 4.5 billion annually. The total projected 5-year societal burden (2025-2029) amounts to BRL 59.4 billion, with IHD representing the largest share of both direct and indirect costs.
conclusionsASCVD imposes a substantial and growing economic burden on Brazilian society, driven primarily by direct healthcare expenditures and productivity losses from premature deaths. These findings highlight the need for strengthened prevention, early detection, and risk-factor management strategies to mitigate the clinical and economic impact of atherosclerotic disease in Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.